AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
5.93
-0.15 (-2.47%)
Aug 7, 2026, 4:00 PM EDT - Market closed
AN2 Therapeutics Employees
AN2 Therapeutics had 21 employees as of December 31, 2025. The number of employees decreased by 1 or -4.55% compared to the previous year.
Employees
21
Change (1Y)
-1
Growth (1Y)
-4.55%
Revenue / Employee
n/a
Profits / Employee
-$1,645,381
Market Cap
213.58M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | -1 | -4.55% | 21 | 0 |
| Dec 31, 2024 | 22 | -19 | -46.34% | 22 | 0 |
| Dec 31, 2023 | 41 | 5 | 13.89% | 41 | 0 |
| Mar 31, 2023 | 36 | 14 | 63.64% | 35 | 1 |
| Dec 31, 2022 | 36 | 14 | 63.64% | 35 | 1 |
| Sep 30, 2022 | 27 | 5 | 22.73% | 26 | 1 |
| Jun 30, 2022 | 25 | - | - | 25 | 0 |
| Mar 31, 2022 | 22 | - | - | 22 | 0 |
| Dec 31, 2021 | 22 | - | - | 22 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Invivyd | 122 |
| Arcturus Therapeutics Holdings | 111 |
| Keros Therapeutics | 87 |
| Compugen | 75 |
| Camp4 Therapeutics | 48 |
| NovaBridge Biosciences | 30 |
| Galectin Therapeutics | 9 |
ANTX News
- 21 days ago - AN2 Therapeutics initiated with a Buy at Guggenheim - TheFly
- 21 days ago - AN2 Therapeutics initiated with a Buy at Guggenheim - TheFly
- 7 weeks ago - The Healthcare M&A Wave - Forbes
- 2 months ago - AN2 Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 2 months ago - AN2 Therapeutics reports data from two studies of AN2-502998 in Chagas disease - TheFly
- 2 months ago - AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease - Business Wire
- 2 months ago - AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference - Business Wire
- 2 months ago - AN2 Therapeutics Transcript: Stifel 2026 Targeted Oncology Virtual Forum - Transcripts